Abstract
The clinical aspects of leishmaniasis encompass a spectrum of signs and symptoms. These range from the nodular or ulcerative lesion seen in cutaneous leishmaniasis which, for some Leishmania species, can evolve to mucocutaneous leishmaniasis after dissemination and invasion of the mouth and upper respiratory tract. Further dissemination leads to a rare syndrome known as diffuse cutaneous leishmaniasis. The systemic and most invasive form of the disease is visceral leishmaniasis. These diseases are not only dependent on the infecting Leishmania species, but also on the immunological status of the host. This chapter will address aspects of clinical presentation of leishmaniases both in the immunocompetent and immunocompromised individuals.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Amato VS, et al. Treatment of mucosal leishmaniasis in Latin America: systematic review. Am J Trop Med Hyg. 2007;77(2):266–74.
Amato VS, et al. Can we use a lower dose of liposomal amphotericin B for the treatment of mucosal American leishmaniasis? Am J Trop Med Hyg. 2011;85(5):818–9.
Ansari NA, Ramesh V, Salotra P. Interferon (IFN)-gamma, tumor necrosis factor-alpha, interleukin-6, and IFN-gamma receptor 1 are the major immunological determinants associated with post-kala azar dermal leishmaniasis. J Infect Dis. 2006;194(7):958–65.
Baba CS, et al. Chronic diarrhea and malabsorption caused by Leishmania donovani. Indian J Gastroenterol. 2006;25(6):309–10.
Bennett JE, Dolin R, Blaser MJ. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases, vol. 2. 8th ed. Philadelphia: Elsevier; 2015.
Bern C, et al. Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg. 2000;63(3–4):184–8.
Boggild AK, et al. Clinical and demographic stratification of test performance: a pooled analysis of five laboratory diagnostic methods for American cutaneous leishmaniasis. Am J Trop Med Hyg. 2010;83(2):345–50.
Develoux M, et al. Diffuse cutaneous leishmaniasis due to Leishmania major in Senegal. Trans R Soc Trop Med Hyg. 1996;90(4):396–7.
Dowlati Y. Cutaneous leishmaniasis. Clinical aspect. Clin Dermatol. 1996;14(5):425–31.
Garcia LS. Diagnostic medical parasitology, vol. xxii. 6th ed. Washington: ASM Press; 2016. p. 1388.
Gonzalez U, et al. Interventions for old world cutaneous leishmaniasis. Cochrane Database Syst Rev. 2008;4:CD005067.
Gonzalez U, et al. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev. 2009;2:CD004834.
Guerra JA, et al. Mucosal Leishmaniasis caused by Leishmania (Viannia) braziliensis and Leishmania (Viannia) guyanensis in the Brazilian Amazon. PLoS Negl Trop Dis. 2011;5(3):e980.
Guerrant RL, Walker DH, Weller PF. Tropical infectious diseases: principles, pathogens and practice, vol. xxiv. 3rd ed. Edinburgh: Elsevier; 2011. p. 1130.
Herwaldt BL, Arana BA, Navin TR. The natural history of cutaneous leishmaniasis in Guatemala. J Infect Dis. 1992;165(3):518–27.
Jones TC, et al. Epidemiology of American cutaneous leishmaniasis due to Leishmania braziliensis braziliensis. J Infect Dis. 1987;156(1):73–83.
Magill AJ. Hunter’s tropical medicine and emerging infectious diseases, vol. xxiv. 9th ed. London: Elsevier; 2013. p. 1190.
Magill AJ, et al. Visceral infection caused by Leishmania tropica in veterans of operation desert storm. N Engl J Med. 1993;328(19):1383–7.
Marovich MA, et al. Leishmaniasis recidivans recurrence after 43 years: a clinical and immunologic report after successful treatment. Clin Infect Dis. 2001;33(7):1076–9.
Marsden PD. Mucosal leishmaniasis (“espundia” Escomel, 1911). Trans R Soc Trop Med Hyg. 1986;80(6):859–76.
Motta AC, et al. Disseminated mucocutaneous leishmaniasis resulting from chronic use of corticosteroid. Int J Dermatol. 2003;42(9):703–6.
Murray HW. Leishmaniasis in the United States: treatment in 2012. Am J Trop Med Hyg. 2012;86(3):434–40.
Pintado V, et al. Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study. Medicine (Baltimore). 2001;80(1):54–73.
Ramesh V, Mukherjee A. Post-kala-azar dermal leishmaniasis. Int J Dermatol. 1995;34(2):85–91.
Reithinger R, Dujardin JC. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol. 2007;45(1):21–5.
Seaman J, Mercer AJ, Sondorp E. The epidemic of visceral leishmaniasis in western upper Nile, southern Sudan: course and impact from 1984 to 1994. Int J Epidemiol. 1996;25(4):862–71.
Shirian S, et al. Three Leishmania/L. species—L. infantum, L. major, L. tropica—as causative agents of mucosal leishmaniasis in Iran. Pathog Glob Health. 2013;107(5):267–72.
Tyring SK, Lupi O, Hengge UR. Tropical dermatology, vol. xi. New York: Elsevier; 2006. p. 515.
Wortmann GW, et al. Cutaneous leishmaniasis following local trauma: a clinical pearl. Clin Infect Dis. 2000;31(1):199–201.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer International Publishing AG
About this chapter
Cite this chapter
Mejia, R. (2018). Clinical Aspects in Immunocompetent and Immunocompromised Patients. In: Bruschi, F., Gradoni, L. (eds) The Leishmaniases: Old Neglected Tropical Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-72386-0_6
Download citation
DOI: https://doi.org/10.1007/978-3-319-72386-0_6
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-72385-3
Online ISBN: 978-3-319-72386-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)